| Primary information |
|---|
| sequence ID | Seq_3119 |
| Peptide sequence | GRDGNPGNDGPPGRDGQPGHKGERGYPG |
| CancerPDF_ID | CancerPDF_ID10986, CancerPDF_ID10987, |
| PMID | 21805675,21805675 |
| Protein Name | Collagen alpha-2(I) chain,Collagen alpha-2(I) chain |
| UniprotKB Entry Name | CO1A2_HUMAN,CO1A2_HUMAN |
| Fluid | Urine,Urine |
| M/Z | 2865.2657,2881.2582 |
| Charge | NA,NA |
| Mass (in Da) | NA,NA |
| fdr | NA,NA |
| Profiling Technique | MALDI-TOF,MALDI-TOF |
| Peptide Identification technique | MALDI-TOF-MS,MALDI-TOF-MS |
| Quantification Technique | NA,NA |
| Labelled/Label Free | Label Free,Label Free |
| FDR | 1,1 |
| CancerPDF_ID | CancerPDF_ID10986, CancerPDF_ID10987, |
| p-Value | NA,NA |
| Software | NA,NA |
| Length | 28,28 |
| Cancer Type | Muscle-invasive bladder cancer,Muscle-invasive bladder cancer |
| Database | SwissProt Database,SwissProt Database |
| Modification | "Oxidation: 6, 12, 18, 27","Oxidation: 6, 11, 12, 18, 27" |
| Number of Patients | 751 bladder cancer and 127 control,751 bladder cancer and 127 control |
| Regulation | Differentially expressed between cancer vs normal samples,Differentially expressed between cancer vs normal samples |
| Validation | Mann-Whitney tests and areas under receiver-operator characteristic,Mann-Whitney tests and areas under receiver-operator characteristic |
| Sensitivity | NA,NA |
| Specificity | NA,NA |
| Accuracy | NA,NA |
| Peptide Atlas | NA |
| IEDB | |
| Primary information |
|---|
| sequence ID | Seq_3120 |
| Peptide sequence | GRDGNpGNDGPpGRDGQpGHKGERGYpG |
| CancerPDF_ID | CancerPDF_ID3777, |
| PMID | 27026199 |
| Protein Name | Collagen alpha-2(I) chain |
| UniprotKB Entry Name | CO1A2_HUMAN |
| Fluid | Urine |
| fdr | 2864.23 |
| Profiling Technique | "CE-MS, Micro-TOF-MS" |
| Peptide Identification technique | MS-MS |
| Labelled/Label Free | Label Free |
| CancerPDF_ID | CancerPDF_ID3777, |
| p-Value | less than 0.05 |
| Software | Proteome Discoverer 1.2 |
| Length | 28 |
| Cancer Type | Bladder cancer |
| Database | Uniprot Human non-redundant Database |
| Modification | p:Hydroxy-Proline |
| Number of Patients | 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls) |
| Regulation | Differentially expressed between recurrence of UBC vs recurrence control |
| Validation | Independent Validation |
| Sensitivity | For testing dataset 88% |
| Specificity | For testing dataset 51% |
| Accuracy | NA |
| Peptide Atlas | NA |
| IEDB | NA |